News
NICE publishes guidance on Astellas’ Xospata
The National Institute for Health and Care Excellence has now published final guidance backing NHS use of Astellas’ Xospata as monotherapy for adults with relapsed or refractory FLT3 mutation-positive acute myeloid leukaemia (AML).